NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

SQBG

Sequential Brands Group, Inc. Common Stock NASDAQ Capital Market
$11.66
Open: $12.7 High: $13.5 Low: $9.959 Close: $11.28
Range: 2021-05-06 - 2021-05-07
Volume: 475,216
Market: Closed
Powered by Finage Stock APIDelayed data
SQBG
Sequential Brands Group, Inc. Common Stock 601 West 26th Street New York NY, 10001 http://www.sequentialbrandsgroup.com
Sequential Brands Group Inc is an apparel licensing and brand management company that owns, promotes, markets and licenses a portfolio of consumer brands in the fashion, active and lifestyle categories.
  • CEO: Karen Murray
  • Employees: 144
  • Sector: Consumer Cyclical
  • Industry: Manufacturing - Apparel & Furniture
SQBG News
Latest news about the SQBG
  • SQBG EQUITY NOTICE: ROSEN, FIRST FILING TOP RANKED INVESTOR COUNSEL, Encourages Sequential Brands Group, Inc. Investors to Secure Counsel Before Important May 17 Deadline in Securities Class Action – SQBG

    NEW YORK, NY / ACCESSWIRE / May 6, 2021 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Sequential Brands Group, Inc. (NASDAQ:SQBG) between November 3, 2016 and December 11, 2020, inclusive (the "Class Period"), of the important May 17, 2021lead plaintiff deadline.

    View More →
  • SQBG, CYDY & RIDE Investor Alerts: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Investors to Contact the Firm

    NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq.

    View More →
  • Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bellus Health, Neptune Wellness, Sequential Brands, and CytoDyn and Encourages Investors to Contact the Firm

    NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bellus Health, Inc. (NASDAQ: BLU), Neptune Wellness Solutions, Inc. (NASDAQ: NEPT), Sequential Brands Group, Inc. (NASDAQ: SQBG), and CytoDyn, Inc. (Other OTC: CYDY). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Bellus Health, Inc. (NASDAQ: BLU) Class Period: September 5, 2019 to July 5, 2020 Lead Plaintiff Deadline: May 17, 2021 Bellus is a clinical-stage biopharmaceutical company whose lead product is BLU-5937, which is being developed for the treatment of chronic cough (one that lasts over eight weeks) and other afferent hypersensitization-related disorders. Before markets opened on July 6, 2020, defendants revealed the truth about BLU5937’s efficacy. They announced that the drug had failed a Phase 2 study of chronic cough patients for whom other treatments had not worked. Specifically, BLU-5937 was not significantly better than a placebo at reducing the frequency at which patients coughed. The Phase 2 trial showed a “clinically meaningful and highly statistically significant” effect only on a subset of patients who had high cough counts (around 32 per day), so the Company was planning a Phase 2b trial focused on those patients. On this news, indicating that Bellus had fallen even further behind Merck in developing an FDA-approved treatment for refractory chronic cough, the Company’s stock price plummeted over 75% to close at $2.97 on July 8, 2020. The complaint, filed on March 16, 2021, alleges that defendants’ scheme: (i) deceived the investing public regarding Bellus’s business, operations, drug products, drug product development, competition, and present and future business prospects; (ii) facilitated the Company’s September 2019 public offering (“Offering”); (iii) created artificial demand for the Bellus common shares sold in the Offering; (iv) enabled the Company to receive approximately $70 million in net proceeds from the sale of Bellus common stock in the Offering; and (v) caused Plaintiff and the Class to purchase Bellus publicly traded common stock at artificially inflated prices. For more information on the Bellus Health class action go to: https://bespc.com/cases/BLU Neptune Wellness Solutions, Inc. (NASDAQ: NEPT) Class Period: July 24, 2019 to February 16, 2021 Lead Plaintiff Deadline: May 17, 2021 On May 9, 2019, Neptune announced that it had signed a definitive agreement to acquire the assets of SugarLeaf Labs, LLC and Forest Remedies LLC (collectively, “SugarLeaf”), a registered North Carolina-based commercial hemp company providing extraction services and formulated products (the “SugarLeaf Acquisition”). On July 24, 2019, Neptune announced the closing of the SugarLeaf Acquisition. On February 15, 2021, Neptune announced disappointing financial results for the third quarter of the Company’s fiscal year 2021, missing analyst expectations. Among other results, Neptune reported third quarter revenues of CA$3.32 million and a net loss of CA$73.8 million, down 63.81% and over 1,000% year-over-year, respectively. Neptune attributed the net loss, in part, to a CA$35.6 million impairment of goodwill and a CA$2.1 million impairment of “property, plant and equipment and right-of-use assets related to the acquisition of SugarLeaf in July 2019,” as well as accelerated amortization of CA$13.95 million “also related to the SugarLeaf acquisition.” Additionally, the Company disclosed that its “[g]ross margin declined to a loss of 268.3%,” which included a non-cash CA$7.39 million “write-down of inventory and deposits to reflect their net realizable value.” On this news, Neptune’s stock price fell $0.86 per share, or 30.71%, to close at $1.94 per share on February 16, 2021. Then, on February 17, 2021, prior to the start of the day’s trading session, Neptune issued a press release announcing the termination of an at-the-market offering conducted by the Company, selling 9,570,735 of its common shares and raising approximately $18.6 million in gross proceeds. Just minutes later, Neptune issued a second press release announcing that the Company was conducting a $55 million registered direct offering. On this news, Neptune’s stock price fell another $0.21 per share, or 10.82%, to close at $1.73 per share on February 17, 2021. The complaint, filed on March 16, 2021, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) the cost of Neptune’s integration of the assets and operations acquired in the SugarLeaf Acquisition would be larger than the Company had acknowledged, placing significant strain on the Company’s capital reserves; (ii) accordingly, it was reasonably foreseeable that the company would need to conduct additional stock offerings to raise more capital; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times. For more information on the Neptune Wellness class action case go to: https://bespc.com/cases/NEPT Sequential Brands Group, Inc. (NASDAQ: SQBG) Class Period: November 3, 2016 to December 11, 2020 Lead Plaintiff Deadline: May 17, 2021On February 28, 2018, Sequential Brands Group issued a press released entitled “Sequential Brands Group Announces Fourth Quarter and Full Year 2017 Financial Results” which belatedly announced the goodwill adjustment. On this news, Sequential Brands Group’s stock price fell $6.80 per share, or 8%, to close at $76.00 per share on February 28, 2018. Then on December 11, 2020, the SEC filed a Complaint alleging that the Company failed “to take into consideration clear, objective evidence of likely goodwill impairment, which avoided and delayed a material write down to goodwill in the fourth quarter of 2016 and the first three quarters of 2017 (the ‘Relevant Period’).” On this news, Sequential Brands Group’s stock price fell $2.03 per share, or 11%, to close at $16.20 per share on December 11, 2020. The complaint, filed on March 16, 2021, alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) in late 2016, the Company knew or should have known that its goodwill was likely impaired; (2) the Company avoided and delayed the material write down to goodwill in late 2016 through 2017; (3) the Company understated its operating expenses and net loss and also materially overstated its income from operations, goodwill, and assets from late 2016 through 2017; (4) the Company’s internal controls were deficient; (5) the Company has failed to restate, correct, or disclose relevant improprieties, deceptive conduct, misstatements, omissions, and control violations; (6) as a result of the foregoing, the Company was at greater risk of regulatory scrutiny and enforcement; and (7) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. For more information on the Sequential Brands class action go to: https://bespc.com/cases/SQBG CytoDyn, Inc. (Other OTC: CYDY) Class Period: March 27, 2020 to March 9, 2021 Lead Plaintiff Deadline: May 17, 2021 CytoDyn is focused on the development and commercialization of a drug named “Leronlimab” which has long been promoted as a potential therapy for HIV patients. Since the beginning of the global COVID-19 pandemic, however, CytoDyn has begun to aggressively tout Leronlimab as a treatment for COVID-19. Beginning on March 5, 2021 CytoDyn began issuing press releases that described the results of Phase IIb/III testing data. In these releases, CytoDyn disclosed that the primary endpoint for the Leronlimab study (all-cause mortality at Day 28) was not statistically significant. After closing at $4.05 on March 5, 2021, CytoDyn shares dropped over 28% to close at $2.91 on March 8, 2021. On March 9, 2021, CytoDyn shares dropped an additional 19% to close at $2.35. The complaint, filed on March 17, 2021, alleges that defendants violated provisions of the Exchange Act by making false and misleading statements concerning Leronlimab being used as a treatment for Covid-19. For more information on the CytoDyn class action go to: https://bespc.com/cases/CYDY About Bragar Eagel & Squire, P.C.:Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information:Bragar Eagel & Squire, P.C.Brandon Walker, Esq. Melissa Fortunato, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

    View More →
  • FINAL DEADLINE IMMINENT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sequential Brands Group, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / May 5, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sequential Brands Group, Inc. ("Sequential Brands" or "the Company") (NASDAQ:SQBG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.

    View More →
  • ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sequential Brands Group, Inc. Investors to Secure Counsel Before Important May 17 Deadline in Securities Class Action - SQBG

    New York, New York--(Newsfile Corp. - May 4, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Sequential Brands Group, Inc. (NASDAQ: SQBG) between November 3, 2016 and December 11, 2020, inclusive (the "Class Period"), of the important May 17, 2021 lead plaintiff deadline.SO WHAT: If you purchased Sequential securities during the Class Period you may be entitled to compensation without payment of any out of ...

    View More →
  • SQBG, CYDY & RIDE Investor Alerts: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm

    NEW YORK, NY / ACCESSWIRE / May 4, 2021 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq.

    View More →
  • Jessica Simpson Looking to Buy Back Her Brand: Sources

    The celebrity is said to be working with Threadstone to raise money and buy the business back from Sequential Brands.

    View More →
  • INVESTOR DEADLINE THIS MONTH: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sequential Brands Group, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / May 3, 2021 /The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sequential Brands Group, Inc. ("Sequential Brands" or "the Company") (NASDAQ:SQBG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.

    View More →
  • ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Sequential Brands Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SQBG

    NEW YORK, May 02, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Sequential Brands Group, Inc. (NASDAQ: SQBG) between November 3, 2016 and December 11, 2020, inclusive (the “Class Period”), of the important May 17, 2021 lead plaintiff deadline. SO WHAT: If you purchased Sequential securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Sequential class action, go to https://www.rosenlegal.com/cases-register-2006.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 17, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) in late 2016, Sequential knew or should have known that its goodwill was likely impaired; (2) Sequential avoided and delayed the material write down to goodwill in late 2016 through 2017; (3) Sequential understated its operating expenses and net loss and also materially overstated its income from operations, goodwill, and assets from late 2016 through 2017; (4) Sequential’s internal controls were deficient; (5) Sequential has failed to restate, correct, or disclose relevant improprieties, deceptive conduct, misstatements, omissions, and control violations; (6) as a result of the foregoing, Sequential was at greater risk of regulatory scrutiny and enforcement; and (7) as a result, defendants’ statements about Sequential’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Sequential class action, go to https://www.rosenlegal.com/cases-register-2006.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 lrosen@rosenlegal.com pkim@rosenlegal.com cases@rosenlegal.com www.rosenlegal.com

    View More →
  • Rosen, Top Ranked Investor Counsel, Encourages Sequential Brands Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SQBG

    New York, New York--(Newsfile Corp. - April 30, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Sequential Brands Group, Inc. (NASDAQ: SQBG) between November 3, 2016 and December 11, 2020, inclusive (the "Class Period"), of the important May 17, 2021 lead plaintiff deadline.SO WHAT: If you purchased Sequential securities during the Class Period you may be entitled to compensation without payment of any out ...

    View More →
  • SQBG, CYDY & RIDE Upcoming Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm

    NEW YORK, NY / ACCESSWIRE / April 30, 2021 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq.

    View More →
  • SHAREHOLDER DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sequential Brands Group, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / April 29, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sequential Brands Group, Inc. ("Sequential Brands" or "the Company") (NASDAQ:SQBG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.

    View More →
  • SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sequential Brands Group, Inc. - SQBG

    New York, New York--(Newsfile Corp. - April 28, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Sequential Brands Group, Inc. ("Sequential" or the "Company") (NASDAQ: SQBG). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Sequential and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about ...

    View More →
  • FINAL DEADLINE APPROACHING: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sequential Brands Group, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / April 28, 2021 /The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sequential Brands Group, Inc. ("Sequential Brands" or "the Company") (NASDAQ:SQBG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.

    View More →
  • SQBG, CYDY & RIDE Shareholder Alerts: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm

    NEW YORK, April 28, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Sequential Brands Group, Inc. (NASDAQ: SQBG) Class Period: November 3, 2016 - December 11, 2020Deadline: May 17, 2021For more info: www.bgandg.com/sqbgThe complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, and failed to disclose that: (1) in late 2016, the Company knew or should have known that its goodwill was likely impaired; (2) the Company avoided and delayed the material write down to goodwill in late 2016 through 2017; (3) the Company understated its operating expenses and net loss and also materially overstated its income from operations, goodwill, and assets from late 2016 through 2017; (4) the Company’s internal controls were deficient; (5) the Company has failed to restate, correct, or disclose relevant improprieties, deceptive conduct, misstatements, omissions, and control violations; (6) as a result of the foregoing, the Company was at greater risk of regulatory scrutiny and enforcement; and (7) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. CytoDyn, Inc. (OTCMKT: CYDY)Class Period: March 27, 2020 - March 9, 2021Deadline: May 17, 2021For more info: www.bgandg.com/cydy The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, and failed to disclose that: (1) while CytoDyn's stock price was sufficiently pumped with the COVID-19 cure hype, long-term shareholders, including CEO Nader Z. Pourhassan and CFO Michael Mulholland, dumped millions of shares; (2) CytoDyn engaged in a wrongful scheme with its lender, Iliad Research and Trading L.P. ("Iliad"), and its principal John Fife ("Fife"), whereby Iliad and other Fife entities operated as an unregistered securities dealer for CytoDyn; and (3) Iliad obtained a convertible promissory note from CytoDyn and converted the note into newly issued shares of CytoDyn and sold those shares into the public market at a profit, in violation of the dealer registration requirements of the federal securities laws. Lordstown Motors Corp. (NASDAQ: RIDE)Class Period: August 3, 2020 - March 24, 2021Deadline: May 17, 2021For more info: www.bgandg.com/ride The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, and failed to disclose that: Specifically, the complaint alleges that BELLUS (1) deceived the investing public about its business, operations, drug products, drug product development, competition, and present and future business prospects; (2) facilitated the Company’s September 2019 public offering (“Offering”); (3) created artificial demand for the BELLUS common shares sold in the Offering; (4) enabled the Company to receive approximately $70 million in net proceeds from the sale of BELLUS common stock in the Offering; and (5) caused Plaintiff and the Class to purchase BELLUS publicly traded common stock at artificially inflated prices. Contact:Bronstein, Gewirtz & Grossman, LLCPeretz Bronstein or Yael Hurwitz 212-697-6484 | info@bgandg.com

    View More →
  • SQBG INVESTOR NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Sequential Brands Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - SQBG

    WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Sequential Brands Group, Inc. (NASDAQ: SQBG) between November 3, 2016 and December 11, 2020, inclusive (the "Class Period"), of the important May 17, 2021 lead plaintiff deadline.

    View More →
  • NASDAQ: SQBG Investor Notice: Lawsuit against Sequential Brands Group, Inc. announced by Shareholders Foundation

    SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Sequential Brands Group, Inc. (NASDAQ: SQBG) shares. Investors, who purchased shares of Sequential Brands Group, Inc. (NASDAQ: SQBG) prior to November 2016 and continue to hold any of their NASDAQ: SQBG shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On March 16, 2021, a lawsuit was filed against Sequential Brands Group, Inc. over alleged violations of securities laws. The plaintiff alleged that the defendants made false and/or misleading statements and/or failed to disclose that in late 2016, the Company knew or should have known that its goodwill was likely impaired, that the Company avoided and delayed the material write down to goodwill in late 2016 through 2017, that the Company understated its operating expenses and net loss and also materially overstated its income from operations, goodwill, and assets from late 2016 through 2017, that the Company’s internal controls were deficient, that the Company has failed to restate, correct, or disclose relevant improprieties, deceptive conduct, misstatements, omissions, and control violations, that as a result of the foregoing, the Company was at greater risk of regulatory scrutiny and enforcement, and that as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. Those who purchased Sequential Brands Group, Inc. (NASDAQ: SQBG) shares should contact the Shareholders Foundation, Inc. CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 mail@shareholdersfoundation.com 3111 Camino Del Rio North Suite 423 San Diego, CA 92108 The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

    View More →
  • BBC International Snaps Up Heelys From Sequential Brands for $11 Million

    "We believe the brand is in great hands under BBC’s leadership going forward," says Sequential Brands Group executive chairman William Sweedler.

    View More →
  • SQBG, CYDY & RIDE Upcoming Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm

    NEW YORK, NY / ACCESSWIRE / April 26, 2021 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq.

    View More →
  • Sequential Brands Group Announces Sale of Heelys Brand

    NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Sequential Brands Group, Inc. (Nasdaq:SQBG) announced today that it has closed on the sale of its Heelys brand to BBC International for $11 million in cash proceeds. “The divestiture of the Heelys brand was an outcome of the Board’s exploration of strategic alternatives, a process that is still underway,” said William Sweedler, Executive Chairman of Sequential. “The Heelys brand was originally acquired in 2013 for a net purchase price of approximately $5.5 million (after accounting for cash on the Heelys balance sheet that we received at the time of the 2013 purchase). BBC International has been the core licensee of Heelys since 2013. We believe the brand is in great hands under BBC’s leadership going forward.” The majority of the net proceeds from the sale will be used to pay down debt. About Heelys Founded in 2000, Heelys are patented products that feature a removable wheel located in the heel, transforming the shoes into stealth skates and giving users the freedom to seamlessly transition from walking or running to skating by shifting their weight to their heel. When the wheels are easily removed, the shoe performs just like any other shoe. The Heelys vision is to inspire kids and adults alike to be active, explore their freedom, unleash the fun and be fearless. Heelys are an attitude, a way to express themselves, push their own boundaries and experience the world around them in a truly unique way. About Sequential Brands Group, Inc. Sequential Brands Group, Inc. (Nasdaq: SQBG) owns, promotes, markets, and licenses a portfolio of consumer brands in the active and lifestyle categories. Sequential seeks to ensure that its brands continue to thrive and grow by employing strong brand management, and marketing teams. Sequential has licensed and intends to license its brands in a variety of consumer categories to retailers, wholesalers and distributors in the United States and around the world. For more information, please visit Sequential's website at: www.sequentialbrandsgroup.com. To inquire about licensing opportunities, please email: newbusiness@sbg-ny.com. CONTACT: Media Contact: Sequential Brands Group, Inc. Katherine Nash T: +1 512-757-2566 E: knash@sbg-ny.com

    View More →